Abstract
The new cantharanthine-modified vinca alkaloid vinorelbine (Navelbine) was administered intradermally (ID) to dehaired BALB/c mice. Dose-dependent skin lesions were produced over the range 0.01–0.5 mg/mouse, with complete healing after 9–35 days. Local (ID) injections of hydrocortisone and saline were ineffective at blocking vinorelbine-induced skin ulceration. Topical skin heating to 43°C or cooling to 10°C were also ineffective. In contrast, hyaluronidase, 15 Units ID, following vinorelbine significantly reduced skin lesions. These results show that vinorelbine is a vesicant and that inadvertent extravasations may be managed with subcutaneous injection of the spreading factor enzyme, hyaluronidase.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Binet S, Fellous A, Lataste H, Krikorian A, Couzinier JP, Meninger V (1989) In situ analysis of the action of Navelbine on various types of microtubules using immunofluorescence. Semin Oncol 16 [Suppl 4]: 5
Bodey GP, Yap H-Y, Yap B-S, Valdivieso M (1980) Continuous infusion vindesine in solid tumors. Cancer Treat Rev 7: 39
Canobbio L, Boccardo F, Pastorino G, Brema F, Martini C, Resasco M, Santi L (1989) Phase-II study of Navelbine in advanced breast cancer. Semin Oncol 16(2): 33
Cros S, Wright M, Morimoto M, Lataste H, Couzinier JP, Krikorian A (1989) Experimental antitumor activity of Navelbine (5′-noranhydrovinblastine, vinorelbine). Semin Oncol 16[Suppl 4]: 15
Dorr RT, Alberts DS (1985) Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. J Natl Cancer Inst 74(1): 113
Dorr RT, Jones SE (1979) Inapparent infiltrations associated with vindesine administration. Med Pediatr Oncol 6: 285
Dorr RT, Alberts DS, Stone A, Salmon SE (1983) Cold protection from intradermal (ID) doxorubicin (DOX) ulceration in the mouse. Proc Am Assoc Cancer Res 24: 255
Fellous A, Ohayon R, Vacassin T, Binet S, Lataste H, Krikorian A, Couzinier JP, Meninger V (1989) biochemical effects of Navelbine on tubulin and associated proteins. Semin Oncol 16(2) [Suppl 4]: 9
Friereich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE (1966) Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 50(4): 219
Jackson DV Jr, Sethi VS, Spurr CL, Willard V, White DR, Richards F, Stuart JJ, Muss HB, Cooper MR, Homesley HD, Jobson VW, Castle MC (1981) Intravenous vincristine infusion: Phase I trial. Cancer 48: 2559
James DH, George P (1964) Vincristine in children with malignant solid tumors. J Pediatr 64: 534
LeChevalier T, Brisgand D, Dovillard J-Y, Pujol JL, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigolari S, Gottfried M, Fuffie P, Panizo A, Gaspard M-H, Raviaioli A, Besenval M, Besson F, Martinez A, Berthaud P, Tursz T (1994) Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small lung cancer: Results of a European multicenter trial including 612 patients J Clin Oncol 12: 36
Marty M, Extra JM, Espie M, Leandri S, Besenval M, Krikorian A (1989) Advances in vinca-alkaloids: Navelbine. Nouv Rev Fr Hematol 31: 77
Mathé G, Reizenstein P (1985) Phase I Pharmacologic study of a new vinca alkaloid: Navelbine. Cancer Lett 27: 285
Ribaud P, Gouveia J, Maral R, Potier P, Jasmin C, Mathé G (1981) Phase I study of 5noranhydrovinblastine (navelbine, NVB). Proc Am Assoc Cancer Res 22: 368
Schwartzman J, Levbarg M (1950) Hyaluronidase. Further evaluation in pediatrics. J Pediatr 36: 79
Zenk KE, Dungy CI, Greene GR (1981) Nafcillin extravasation injury: Use of hyaluronidase as an adidote. Am J Dis Child 135: 1113
Author information
Authors and Affiliations
Additional information
Supported by a grant from Burroughs Wellcome Company, Research Triangle Park, North Carolina
Rights and permissions
About this article
Cite this article
Dorr, R.T., Bool, K.L. Antidote studies of vinorelbine-induced skin ulceration in the mouse. Cancer Chemother. Pharmacol. 36, 290–292 (1995). https://doi.org/10.1007/BF00689045
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00689045